drug
LACOSAMIDE
Marketedupdated 3mo agoby UCB SA
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 7- tagApproval16 co-mentions · 8 sources
- druglacosamide ER13 co-mentions · 13 sources
- companyGlenmark Pharmaceuticals Ltd12 co-mentions · 4 sources
- tagSmall Molecule8 co-mentions · 8 sources
- companyHetero Labs Ltd6 co-mentions · 6 sources
- tagRecall6 co-mentions · 5 sources
- companyApotex Corp2 co-mentions · 1 sources
all catalysts(6)
approval · 6
Mar 17, 2022
approval
LACOSAMIDE — FDA approval
LACOSAMIDE
→
Oct 15, 2025
approval
LACOSAMIDE — FDA approval
LACOSAMIDE
→
Oct 15, 2025
approval
LACOSAMIDE — FDA approval
LACOSAMIDE
→
Oct 15, 2025
approval
LACOSAMIDE — FDA approval
LACOSAMIDE
→
Oct 15, 2025
approval
LACOSAMIDE — FDA approval
LACOSAMIDE
→
Oct 15, 2025
approval
LACOSAMIDE — FDA approval
LACOSAMIDE
→
Trials studying LACOSAMIDE
- phase3Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.
- phase2A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
- phase3A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment
- phase2A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).
- phase2An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy
- phase3Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
- phase3Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.
- phase3A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 5, 2040
~13.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (9)
- Jun 5, 2040formulationUS 11337943
- Jun 5, 2040formulationUS 11337943
- Jun 5, 2040formulationUS 11337943
- Jun 5, 2040formulationUS 11883374
- Jun 5, 2040formulationUS 11883374
- Jun 5, 2040formulationUS 11883374
- Jun 5, 2040formulationUS 12042474
- Jun 5, 2040formulationUS 12042474
- Jun 5, 2040formulationUS 12042474
FDA exclusivities (6)
- Apr 28, 2026D-188New Indication (3y)
- Apr 28, 2026D-188New Indication (3y)
- Apr 28, 2026D-188New Indication (3y)
- Apr 28, 2026D-188New Indication (3y)
- Apr 28, 2026D-188New Indication (3y)
- Apr 28, 2026D-188New Indication (3y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 33m ago
Found something off?
comments(0)
5-min edit window · permanent after that